To reduce costs and support development of other platform technologies, aap Implantate will discontinue parts of its standard trauma portfolio by the end of 2019.
Of note, the decision was made against the background of the significantly increased regulatory requirements of the new EU Medical Device Regulation (MDR). The partial discontinuation allows aap to avoid not only the expenditures to adapt processes and documents for these products to the new MDR, but also the costs to maintain certification.
aap will concentrate on distribution of its higher-margin LOQTEQ® plating systems and its range of cannulated screws, and further development and market approval of its silver coating technology and resorbable magnesium implants.
The standard trauma business presently comprises various plate/screw sets for mini, small and large fragments, including dynamic hip and condylar plates and also non-locking acromioclavicular plates.
Sales of the products that will be discontinued contributed €0.7MM (~USD $0.8MM) to 2018 revenue.
Source: aap Implantate AG